Gov. Brown vetoes Amgen-backed anti-biosimilars bill
Gov. Jerry Brown vetoed a bill supported by Thousand Oaks-based Amgen and other biotechnology companies that would have made it more difficult for pharmacists to dispense so-called biosimilars, the biotech industry’s analogue to generic pharmaceuticals.
Senate Bill 598, approved by both houses of the legislature, looked mostly like a procedural change to state’s pharmacy laws. If it passed, the bill would have allowed pharmacists to fill prescriptions with biosimilars that the U.S. Food and Drug Administration deems “interchangeable” with brand-name counterparts.
Nova Sensors flourishing in Buellton under Teledyne ownership
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Limoneira locks in lemons: Santa Paula firm makes $18.6M buy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dole seeks buyout bidders
Shares of Dole Food, based in Westlake Village, closed above CEO David Murdock’s buyout offer price of $13.50 after the company disclosed in SEC filings that other bidders may be surfacing. In its filing Dole said that “beginning on the morning of Aug. 12” representatives of investment bank Lazard began contacting potential bidders, including four Read More →
Teledyne breaks speed record with testing gear
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ceres loses $9.3M, missing estimates
Thousand Oaks-based agricultural biotech firm Ceres’ third-quarter net loss widened to $9.3 million, or 38 cents per share, on revenue of $1.4 million, it said July 11. The energy crop firm attributed the higher loss to added expenses from expanding business operations in Brazil and higher-than-expected variability in how much fuel its crops can produce. Read More →
Amgen news kicks off Q3 trading: CalAmp frontrunner in first-half standings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
